Y-mAbs Therapeutics, Inc.
YMABDelisted Sep 16, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001722964
Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.
Q3 2024 vs. Q2 2024
How the institutions holding Y-mAbs Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 96 | 1 | 105 | +10 |
| Shares | 24.4M | 2.94M | 25.7M | +4.33M (+20.2%) |
| Value | $294.2M | $35.5M | $338.5M | +$79.9M (+30.9%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Y-mAbs Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 3,025,235 | $39.8M | 0.00% |
| Logos Global Management LP | 800,000 | $10.5M | 1.18% |
| Rafferty Asset Management, LLC | 35,077 | $461.3K | 0.00% |
| Principal Financial Group Inc | 20,294 | $266.9K | 0.00% |
| Empire Financial Management Company, LLC | 16,000 | $210.4K | 0.06% |
| Marshall Wace, LLP | 15,509 | $203.9K | 0.00% |
| HRT Financial LP | 14,260 | $187.0K | 0.00% |
| SG Americas Securities, LLC | 13,566 | $178.0K | 0.00% |
| Intech Investment Management LLC | 10,149 | $133.5K | 0.00% |
| Lazard Asset Management LLC | 4,218 | $55.0K | 0.00% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 3,324 | $43.7K | 0.00% |
| Bessemer Group Inc | 180 | $2.00K | 0.00% |
| Sterling Capital Management LLC | 38 | $500 | 0.00% |
| Lindbrook Capital, LLC | 32 | $421 | 0.00% |
| Smartleaf Asset Management LLC | 31 | $401 | 0.00% |
| Rothschild Investment LLC | 25 | $329 | 0.00% |
| Parallel Advisors, LLC | 18 | $237 | 0.00% |
| US Bancorp | 17 | $224 | 0.00% |
| Allspring Global Investments Holdings, LLC | 8 | $105 | 0.00% |
| Capital Performance Advisors LLP | 3 | $39 | 0.00% |
Sold out (10)
Institutions that held Y-mAbs Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Massachusetts Financial Services Co | 82,202 | $993.0K |
| Balyasny Asset Management LLC | 43,973 | $531.2K |
| Sherbrooke Park Advisers LLC | 23,647 | $285.7K |
| Cubist Systematic Strategies, LLC | 6,597 | $79.7K |
| Danske Bank A/S | 1,276 | $15.4K |
| HighMark Wealth Management LLC | 220 | $2.66K |
| Russell Investments Group, Ltd. | 188 | $2.27K |
| Signaturefd, LLC | 64 | $773 |
| Point72 (DIFC) Ltd | 53 | $637 |
| Advisor Group Holdings, Inc. | 30 | $362 |
Not filed for Q3 2024 yet (1)
Institutions that held Y-mAbs Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,938,718 | $35.5M |